CDH10 (cadherin 10) is a type II classical cadherin that functions as a calcium-dependent cell adhesion molecule mediating homophilic cell-cell interactions 1. As a member of the cadherin superfamily, CDH10 participates in adherens junction organization, beta-catenin binding, and synaptic membrane adhesion, contributing to cell morphogenesis and migration 1. CDH10 has emerged as a tumor suppressor with clinical significance across multiple cancer types. In breast cancer, CDH10 expression is epigenetically silenced by the histone methyltransferase G9a under hypoxic conditions, promoting cell motility and metastasis; CDH10 overexpression reduces cellular migration and prevents hypoxia-induced motility 2. CDH10 is prognostically valuable in breast cancer, with reduced expression associated with lymph node metastasis and poor survival outcomes 3. In pancreatic ductal adenocarcinoma, CDH10 alterations including germline mutations and loss of heterozygosity occur in both familial and sporadic cases, with altered immunohistochemical staining patterns in tumors 4. In gastric and colorectal cancers with high microsatellite instability, CDH10 harbors frameshift mutations that likely inactivate cell adhesion function 5. Additionally, CDH10 is associated with the reproductive subtype of polycystic ovary syndrome in genome-wide association studies 6, and appears as a hub gene in diabetic nephropathy pathophysiology 7. CDH10 dysfunction contributes to cancer progression through reduced cell-cell adhesion and increased cellular motility.